(S (NP (NP (DT The) (NN case)) (SBAR (S (NP (PRP we)) (VP (VBP deal) (PP (IN with)))))) (VP (VBZ is) (VP (VBN set) (PP (IN in) (NP (NP (DT an) (JJ open) (NN market)) (SBAR (WHADVP (WRB where)) (S (NP (JJ global) (NNS players)) (VP (VBP diversify) (PP (IN into) (NP (NP (JJ different) (JJ national) (NNS markets)) (PP (IN of) (NP (JJ pharmaceutical) (NNS generics)))))))))))) (. .))
(S (NP (NN Risk) (NNS issues)) (VP (VBP are) (ADJP (RB significantly) (JJ important) (PP (IN in) (S (VP (VBG deterring) (NP (NN decision) (NNS makers)) (PP (IN from) (S (VP (VBG expanding) (PP (IN in) (NP (DT the) (JJ generic) (JJ pharmaceutical) (NN business))))))))))) (. .))
(S (NP (JJ Small) (, ,) (JJ non-diversified) (NNS generics) (NNS labs)) (VP (VBP are) (PP (IN in) (NP (DT the) (JJR worse) (NN position)))) (. .))
